Medscape October 23, 2024
NEW YORK (Reuters) – Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their Medicaid health programs for low income people, citing cost as a key factor, according to a survey conducted by health research firm KFF.
The survey of the 50 states and the District of Columbia found that just 12 Medicaid programs covered the drugs to treat obesity as of July 2024 with some limits on use.
Half of the states without coverage said they are considering adding them or evaluating their coverage, it said.
The drugs from a class known as GLP-1 agonists were initially developed to treat type 2 diabetes but also promote weight loss by...
Today's Sponsors
Today's Sponsor